Patent ID: 9364566
Filing Date: 2016-06-14
CPC Classification: A61K,A61P

Claim Text:
1. An aqueous formulation useful for targeted gene expression in human cancer cells expressing glucocorticoid receptors and delivery of genetic material to said cancer cells, the formulation comprising: (a) a cationic lipid, (b) a glucocorticoid steroid and (c) a neutral co-lipid, wherein the glucocorticoid steroid improves an efficiency of delivery of the genetic material to human cancer cells expressing glucocorticoid receptors, wherein the cationic lipid, steroid and neutral co-lipid are mixed in a molar ratio in the range of 0.75:0.5:1 to 1:2:1, and wherein the glucocorticoid steroid is selected from the group consisting of dexamethasone, prednisolone, fluprednisolone, betamethasone, methylprednisolone, and triamcinolone.